| High | $10.00 |
|---|---|
| Median | $10.00 |
| Low | $10.00 |
| Average | $10.00 |
| Current Price | $0.80 |
Is EAR stock a good Buy?
Out of 3 analysts, 0 (0%) are recommending EAR as a Strong Buy, 0 (0%) are recommending EAR as a Buy, 2 (66.67%) are recommending EAR as a Hold, 0 (0%) are recommending EAR as a Sell, and 1 (33.33%) are recommending EAR as a Strong Sell.
Why has Eargo stock dropped?
What happened. Shares of Eargo (NASDAQ: EAR), a hearing aid manufacturer, are sinking in response to the disclosure of a federal investigation the company made to investors after markets closed on Wednesday. The medical device stock was down 68.5% as of 10:40 a.m. EDT on Thursday.
Is Eargo a good stock?
Eargo has received a consensus rating of Hold. The company's average rating score is 1.67, and is based on no buy ratings, 2 hold ratings, and 1 sell rating.
Will Eargo stock go up?
Eargo Inc (NASDAQ:EAR) The 1 analysts offering 12-month price forecasts for Eargo Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 10.00. The median estimate represents a +995.41% increase from the last price of 0.91.
Is Eargo under investigation?
Christian Gormsen, Eargo President and Chief Executive Officer, said, “We are pleased that we have now put the DOJ investigation behind us and have done so on such a rapid timeline since learning of the investigation on September 21, 2021.
Who owns Eargo hearing?
EargoTypePublicFoundersFlorent Michel (Inventor) Raphael Michel Daniel ShenHeadquartersSan Jose, California , U.S.Area servedUnited StatesKey peopleChristian Gormsen (President, CEO, and Director)6 more rows
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
EARS's average price target has moved down $0.36 over the prior 0 secs.
EARS Broker Recommendations Summary
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for EARS as an investment opportunity.
Component Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
The Trend in the Analyst Price Target
EAR's average price target has moved down $46.5 over the prior 32 weeks.
EAR Broker Recommendations Summary
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Signals & Forecast
Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Some negative signals were issued as well, and these may have some influence on the near short-term development.
Support, Risk & Stop-loss
There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.
Is Auris Medical Holding AG stock A Buy?
Auris Medical Holding AG holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.
About Auris Medical Holding AG
Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its lead product candidate includes AM-101, which is in Phase III clinical development for treating acute inner ear tinnitus.
Golden Star Signal
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
Why is the target price unavailable?
If the target price is unavailable, it is most likely because there were not enough analyst opinions to come up with a consensus estimate. When setting a price target estimate, an analyst is trying to determine what the Stock is worth and where the price will be in a year from now.
Where do analysts publish their price targets?
Most analysts publish their price targets in research reports on specific companies , along with their buy, hold, or sell recommendations. Stock price targets are often quoted in the financial news media. Macroaxis uses multiple feeds to provide overall target price projection for Auris Medical.
How often does Auris issue ratings?
Most Auris analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Auris stock's fair price compared to its market value.
What is the most common way Auris Medical analysts use to provide recommendation to the public?
The most common way Auris Medical analysts use to provide recommendation to the public is financial statements analysis. Many experts also interview Auris Medical executives and customers to further validate their buy or sell advice.
Historical and forecast chart of Eargo stock
The chart below shows the historical price of Eargo stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Eargo stock price can be found in the table below.
Eargo Daily Price Targets
Forecast target price for 02-23-2022: $ 4.97. Positive dynamics for Eargo shares will prevail with possible volatility of 3.516%.
Eargo forecast for this year
An downtrend is forecast for this month with an optimal target price of $ 4.28414. Pessimistic: $3.50. Optimistic: $4.76
Eargo information and performance
Eargo is an American medical device manufacturer dedicated to improving the quality of life for people with hearing loss. The company developed the Eargo solution to create a hearing aid that consumers will truly want to use.
EAR earnings per share forecast
What is EAR 's earnings per share in the next 2 years based on estimates from 2 analyst s?
EAR revenue forecast
What is EAR 's revenue in the next 2 years based on estimates from 1 analyst?
EAR revenue growth forecast
How is EAR forecast to perform vs Medical Devices companies and vs the US market?
